POC or Point-of-care testing, also known as bedside testing is a diagnostic testing at or close to the point or position of care at the same place and time of patient care. Diagnostic tests have been restricted to the diagnostic centre or medical laboratory, thereby sending off blood samples away from patient care site entailed a waiting period ranging from a few days to a few weeks for the results to arrive. This necessitated continuous care of the patient by the same treatment, devoid of the crucial information and led to the deployment of point of care testing. This in turn led to growth of the cardiac POC testing devices market. POC tests are simple diagnostic tests that may be carried out at the bedside.
Request for PDF of Sample Pages @ https://www.coherentmarketinsights.com/insight/request-sample/192
Cardiac POC testing is a diagnostic test related to the heart that is carried out close to the point of care of the patient. Principally, they are simple blood tests that include coagulation testing and cholesterol testing, among others. Coagulation testing helps doctors assess risk of extreme bleeding or developing thrombosis inside blood vessels in the body, including the heart. Cardiac point-of-care tests include brain natriuretic peptide analysis and Troponin, which are mainly employed to identify cardiovascular ailments such as coronary syndromes, heart failure, and myocardial infarction. Cardiac POC testing device help to detect enzymes that are released at some point in heart failure and in vital cardiac circumstances such as synthesizing troponin, kinase, brain natriuretic peptides and lactate dehydrogenase isoenzymes. Moreover, these tests help doctors detect and distinguish between angina and myocardial infarction, which are two of the major causes of heartache and death related to the same. Cardiac POC significantly decreases the time taken to get the reports. In most cases, the reports are supplied within an hour post submission of the test sample. Thus, cardiac POC tests help reduce turnaround time considerably, thereby allowing for instant patient response and effectual management of cardiac diseases. These functionalities will drive growth of the market in cardiac POC testing devices during the forecast period (2016–2024).
Ask for Discount before buying @ https://www.coherentmarketinsights.com/insight/request-discount/192
Cardiac POC Testing Devices Market Taxonomy
On the basis of product type, the market is classified into:
- Automated molecular tests
- Portable analyzers
- Imaging systems Sequencing By Ligation (SBL)
On the basis of end users, the market is classified into:
- Diagnostic Centres
Cardiac diseases and the conditions leading to them, including hypercholesterolemia, require constant monitoring of the patient and accordingly adjusting the dosage and the combination of drugs prescribed. High cholesterol can also be hereditary in nature. According to the FH Foundation—a global charity focused on increasing awareness regarding Familial Hypercholesterolemia—1 in 200-500 people suffered from familial hypercholesterolemia worldwide in 2015. With increasing population, the number is likely to rise in the future, thereby leading to an increase in demand for testing cholesterol levels in individuals. This in turn would propel overall growth of the cardiac POC testing devices market.
To know the latest trends and insights prevalent in the Cardiac POC Testing Devices Market, click the link below:
Growing prevalence of cardiac diseases, especially in Asia Pacific to drive growth of cardiac POC testing devices market
According to a report published by the Heart Foundation—an Australia-based organization focused on increasing awareness about heart disease—heart disease (including Stroke and other Cardiovascular Diseases) is the main cause of death in the U.S., leading to the death of nearly 787,000 people in 2011. The same report stated that around 720,000 individuals in the U.S. suffer from heart attacks each year. Of these attacks, 515,000 are first heart attacks and the rest 205,000 happened in patients who have already experienced a heart attack. North America is characterized by a robust healthcare infrastructure and is well equipped with technologically advanced instruments such as new age cardiac POC testing devices for monitoring the condition in patients suffering from cardiovascular diseases. These are some of the reasons for dominance of the North America in the global cardiac POC testing devices industry.
However, Asia Pacific is likely to gain significant momentum in the near future. According to a report published by National Centre for Biotechnology Information in 2013, cardiovascular disease (CVD) is the major cause of death in the globe and around half of these CVD cases were expected to be reported in Asia. When compared with the Western world, most Asian countries, excluding Japan, Singapore, Thailand, and South Korea, account for high mortality (age-adjusted) from CVD, thereby augmenting growth of the market.
Some of the major companies operating in the cardiac POC testing devices market in the current scenario are Abbott Laboratories, Alere Inc., BG Medicine Inc., Roche Diagnostics, Beckman Coulter, Inc., Medtronic Inc., and Boston Scientific Corp.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154